

Until now, both direct toxic effects and immune-mediated toxicity have been suggested as possible mechanisms of idiosyncratic liver injury. With direct toxicity, covalent protein binding via AG may disrupt the normal physiological function of a "critical" protein or some critical regulatory pathway, leading to cellular necrosis (Pirmohamed et al., 1996). In addition, it has been reported that electrophilic AG can covalently interact with nucleic acids. For example, clofibrate AG and gemfibrozil AG can form DNA adducts, resulting in genotoxicity that can be measured by the single-cell gel electrophoresis (comet) assay (Sallustio et al., 1997). Furthermore, probenecid and clofibric acid induced DNA damage in isolated hepatocytes and UDP-glucuronosyltransferase (UGT)-transfected HEK293 cells via a glucuronidation-dependent pathway (Sallustio et al., 2006; Southwood et al., 2007). The significance of these findings is not yet clear.

Among UGT isoforms, the glucuronidation of carboxylic acid drugs is mediated by UGT1A3, UGT1A9, or UGT2B7 (Sakaguchi et al., 2004). Of interest, despite high sequence identity (amino acid homology of 93%), human UGT1A3 and UGT1A4 differ in terms of substrate selectivity, i.e., UGT1A3 catalyzes the acyl glucuronidation but UGT1A4 hardly does (Kubota et al., 2007). HEK293 cells can express human recombinant UGTs for cytotoxicity studies and effectively glycosylate them (Nakajima et al., 2010; Nishiyama et al., 2010). Therefore, HEK293 cells stably expressing UGT1A3 (HEK/UGT1A3) and UGT1A4 (HEK/UGT1A4) could be useful for toxicity assessment.

Among the drugs containing the carboxylic acid moieties, naproxen, diclofenac, ketoprofen, and ibuprofen were selected. Naproxen, diclofenac, and ibuprofen infrequently show severe drug-induced liver injury, but ketoprofen almost never does (Cuthbert, 1974; Banks et al., 1995; Boelsterli et al., 1995; Walker, 1997; Riley and Smith, 1998). In addition, these NSAIDs are mainly metabolized to the corresponding AG (Foster et al., 1988; Vree et al., 1993; Castillo and Smith, 1995; Kumar et al., 2002). Direct mechanistic evidence linking the toxicity to the formation of drug-protein adducts is lacking. We focused on toxicity due to cell dysfunction by acyl glucuronide formation. In this study, to clarify whether formation of AG occurred in the cells, rather than exposure to hydrophilic AG from outside the cells, which shows toxicity due to cell dysfunction by the adduct formation *in vitro*, we investigated the cytotoxicity of the NSAIDs exposed to HEK/UGT1A3 or HEK/UGT1A4 and human hepatocytes. Furthermore, we investigated the genotoxicity of the NSAIDs by using the comet assay.

#### Materials and Methods

**Materials.** Ketoprofen, ibuprofen, G418, and dimethyl sulfoxide (DMSO) were purchased from Wako Pure Chemicals (Osaka, Japan). Naproxen acyl- $\beta$ -D-glucuronide, diclofenac acyl- $\beta$ -D-glucuronide, ketoprofen acyl- $\beta$ -D-glucuronide, and ibuprofen acyl- $\beta$ -D-glucuronide were purchased from Toronto Research Chemicals Inc. (North York, ON, Canada). Naproxen, diclofenac sodium salt, UDP-glucuronic acid (UDPGA), alamethicin, 4-methylumbelliferone (4-MU), 4-MU *O*-glucuronide, and (-)-borneol were purchased from Sigma-Aldrich (St. Louis, MO). Rabbit anti-human UGT1A antibodies were obtained from BD Gentest (Woburn, MA). Rabbit anti-human GAPDH antibodies were purchased from Imgenex (San Diego, CA). IRDye 680-labeled goat anti-rabbit secondary antibody and Odyssey Blocking buffer were obtained from LI-COR Biosciences (Lincoln, NE). Primers were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA). All other chemicals and solvents were of the highest grade or the analytical grade commercially available.

**Isolation of Human UGT1A3 and Construction of Expression Vectors.** Human UGT1A3 (accession number NM\_019093) cDNAs were prepared by a reverse transcription-polymerase chain reaction technique using total RNA from human liver. The primer sequences used in this study were as follows: human UGT1A3ex1 sense primer, 5'-TCTTCTGCTGAGATGGCCAC-3' and

human UGT1Aex5 antisense primer, 5'-GCACCTCTGGGGCTGATTAAT-3'. After an initial denaturation at 94°C for 5 min, amplification was performed by denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 90 s for 45 cycles, followed by a final extension at 72°C for 5 min. The polymerase chain reaction products were subcloned into pTARGET Mammalian Expression Vector (Promega, Madison, WI), and the DNA sequences of the inserts were determined using a Thermo Sequenase Cy5.5 Dye Terminator Cycle Sequencing Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK) with a Long-Read Tower DNA sequencer (GE Healthcare).

**Stable Expression of UGT1A3 and UGT1A4 Isoforms in HEK293 Cells.** An expression vector for UGT1A3 was constructed. HEK293 cells (American Type Culture Collection, Manassas, VA) were grown in Dulbecco's modified Eagle's medium containing 4.5 g/l glucose, 10 mM HEPES, and 10% fetal bovine serum with 5% CO<sub>2</sub> at 37°C. The cells in 12-well plates were transfected with 1.6  $\mu$ g of the UGT1A3 expression vector using Lipofectamine 2000. Stable transfectants of UGT1A3 were selected in medium containing 800 mg/l G418. HEK293 cells stably expressing UGT1A4 were previously established in our laboratory (Fujiwara et al., 2007a). The cell lines were incubated with 95% O<sub>2</sub>/5% CO<sub>2</sub> at 37°C and split 1:4 every 3 days.

**SDS-PAGE and Immunoblotting.** Samples were boiled for 3 min in Laemmli sample buffer containing 2-mercaptoethanol and separated on 10% SDS-polyacrylamide gel. The separated proteins were electrotransferred onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore Corporation, Billerica, MA). The membrane was washed with phosphate-buffered saline (PBS) two times and blocked with Odyssey Blocking buffer for 1 h. The membranes were incubated with rabbit anti-human UGT1A polyclonal antibody (1:500) and rabbit anti-human GAPDH antibodies (1:1000) diluted with Odyssey Blocking buffer containing 0.1% Tween 20 for 1 h. The membrane was washed with PBS-T (PBS containing 0.1% Tween 20) four times and incubated with IRDye 680-labeled goat anti-rabbit IgG secondary antibody diluted (1:5000) with PBS-T for 1 h. The densities of the bands were determined using an Odyssey Infrared Imaging System (LI-COR Biosciences).

**HPLC Analysis of 4-MU *O*-Glucuronide Formation on UGT1A3.** 4-MU *O*-glucuronosyltransferase activity was determined as described previously with slight modifications (Fujiwara et al., 2007a). In brief, a typical incubation mixture (100  $\mu$ l of total volume) contained 50 mM Tris-HCl buffer (pH 7.4), 10 mM MgCl<sub>2</sub>, 2.5 mM UDPGA, 25  $\mu$ g/ml alamethicin, 0.4 mg/ml cell homogenate of UGT1A3, and 1 to 1000  $\mu$ M 4-MU. The reaction was initiated by the addition of UDPGA after a 3-min preincubation at 37°C. After incubation at 37°C for 30 min, the reaction was terminated by the addition of 100  $\mu$ l of ice-cold methanol. After removal of the protein by centrifugation at 13,000g for 5 min, a 50- $\mu$ l portion of the sample was subjected to HPLC. The analytical column was a CAPCEL PAK C18 UG120 (4.6  $\times$  150 mm, 5  $\mu$ m; Shiseido, Tokyo, Japan), and the mobile phase was 30% methanol-20 mM potassium phosphate buffer (pH 4.5). The eluent was monitored at 320 nm. The quantification of 4-MU *O*-glucuronide was performed by comparing the HPLC peak height with that of the authentic standard. Kinetic parameters were estimated from the fitted curve using a computer program (Kaleidagraph; Synergy Software, Reading, PA) designed for nonlinear regression analysis. The following equation was applied for Michaelis-Menten kinetics:

$$V = V_{\max} \cdot S / (K_m + S)$$

where  $V$  is the velocity of the reaction,  $S$  is the substrate concentration,  $K_m$  is the Michaelis-Menten constant, and  $V_{\max}$  is the maximum velocity. Data are expressed as means  $\pm$  S.D. of triplicate determinations.

**In Vitro Studies with HEK/UGT Cells.** *Cytotoxicity assay.* HEK/UGT cells were seeded into 96-well microtiter plates layered with  $2 \times 10^4$  cells/well in 0.1 ml of 0.5% (v/v) FBS supplemented DMEM and were immediately incubated with naproxen (1 mM), diclofenac (0.1 mM), ketoprofen (1 mM), or ibuprofen (1 mM) for 6, 12, or 24 h.

*Quantification of the AG metabolites.* HEK/UGT cells were seeded into 24-well plates layered with  $2 \times 10^5$  cells/well in 1 ml of 0.5% (v/v) FBS-supplemented DMEM and were immediately incubated with the NSAIDs for 6, 12, or 24 h. The cultured cells were collected into a clean tube after the specified period and then centrifuged at 3000g for 5 min to separate the cultured medium and cell fraction. The cell fraction was suspended with 100  $\mu$ l of PBS. We confirmed the stability of each AG in the autosampler at 4°C

for 24 h (data not shown). The final concentrations of DMSO in the culture medium did not exceed 0.1%.

**In Vitro Studies with Human Hepatocytes.** *Cytotoxicity assay.* LiverPool cryopreserved human hepatocytes in suspension (Celsis In Vitro Technologies, Brussels, Belgium) were seeded into collagen-coated 96-well microtiter plates layered with  $2 \times 10^4$  cells/well in 0.1 ml of 0.5% (v/v) FBS-supplemented HCM culture medium (epidermal growth factor- and antibiotic-free) containing 10 nM estradiol and were immediately preincubated with (-)-borneol (1 mM), an inhibitor of acyl glucuronidation. After 30 min, the cells were incubated with the NSAIDs for 6 h.

*Quantification of the NSAIDs and their AG metabolites.* Human hepatocytes were seeded into collagen-coated 24-well plates layered with  $2 \times 10^5$  cells/well in 1 ml of 0.5% (v/v) FBS-supplemented HCM culture medium and were immediately preincubated with (-)-borneol (1 mM). After 30 min, the cells were incubated with 0.5% (v/v) FBS-supplemented HCM culture medium containing the NSAIDs for 6 h. We confirmed the stability of each AG at 4°C for 24 h (data not shown). The final concentrations of DMSO in the culture medium did not exceed 0.2%.

**LC-MS/MS Analysis and Preparation of AG Samples.** The NSAIDs and their AGs were quantified using PE SCIEX API 2000 LC-MS/MS systems (MDS Sciex, Concord, ON, Canada) equipped with an electrospray ionization interface used to generate negative ions  $[M - H]^-$ . The test drugs were separated on a ZORBAX SB-C18 column ( $50 \times 2.1$  mm, 3.5  $\mu$ m; Agilent Technologies, Santa Clara, CA). The gradient mobile phase consisted of 0.1% formic acid in purified water and 0.1% formic acid in methanol (80:20 to 10:90, v/v). The mobile phase was eluted at 0.2 ml/min using an Agilent 1100 series pump (Agilent Technologies). The NSAIDs and their AGs were monitored by multiple reaction monitoring using transitions of 229  $\rightarrow$  169 (naproxen), 405  $\rightarrow$  193 (naproxen AG), 294  $\rightarrow$  250 (diclofenac), 470  $\rightarrow$  193 (diclofenac AG), 253  $\rightarrow$  209 (ketoprofen), 429  $\rightarrow$  193 (ketoprofen AG), 205  $\rightarrow$  161 (ibuprofen), and 381  $\rightarrow$  193 (ibuprofen AG). These drugs were calculated by comparing the peak area to that of the authentic standard. The analytical data were processed using Analyst software (version 1.4.1; Applied Biosystems, Foster City, CA) in the API2000 LC-MS/MS systems.

Fifty microliters of methanol-acetic acid (100:1, v/v) was added to a 50- $\mu$ l portion of the cell fraction or the cultured medium, and then the mixture was centrifuged at 17,400g for 10 min. The supernatant was transferred to a glass vial kept at 4°C in an autosampler, and 20  $\mu$ l of this solution was injected.

**Cytotoxicity Assays.** An MTT assay was performed with a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) using water-soluble [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulphophenyl)-2H-tetrazolium monosodium salt] (WST-8). WST-8 produces a water-soluble formazan dye upon reduction in the presence of an electron carrier coupling with mitochondrial dehydrogenases. HEK/UGT cells or human hepatocytes (each  $2 \times 10^4$  cell/well) were seeded in 96-well plates. After 6, 12, and 24 h of incubation for HEK/UGT cells (or after 6 h of incubation for human hepatocytes), CCK-8 reagent was added, and the absorbance of WST-8 formazan at 450 nm was measured according to the manufacturer's instructions. The percent cell viability was calculated by comparing absorbance of cells with that of the control cells.

Cell viabilities of the HEK/UGT cells and human hepatocytes were also evaluated by the intracellular ATP concentration using a CellTiter-Glo Luminescent Cell Viability Assay (Promega). The luminescence of the oxyluciferin generated was measured in the presence of an electron carrier coupling with mitochondrial dehydrogenases. HEK/UGT cells or human hepatocytes (each  $2 \times 10^4$  cell/well) were seeded in 96-well plates. After 6, 12, and 24 h of incubation for HEK/UGT cells (or after 6 h of incubation for human hepatocytes), CCK-8 reagent was added, and the absorbance of WST-8 formazan at 450 nm was measured according to the manufacturer's instructions. The percent cell viability was calculated by comparing cell luminescence with that of the control cells.

Lactate dehydrogenase (LDH) leakage from HEK/UGT cells was evaluated by a Cytotoxicity Detection Kit-LDH (Roche Diagnostics GmbH, Mannheim, Germany). LDH release was measured photometrically at 490 nm (690 nm reference) according to the manufacturer's instructions. The maximum LDH release control was prepared as well as the timing of the addition of lysis solution (1% Triton X-100) to obtain 100% LDH release. The percentage of LDH release was calculated by comparing the absorbance to the maximum LDH release of the control cells.

**Comet Assay.** The alkaline version of the comet assay is a sensitive genotoxicity test for the detection of DNA strand breaks. The comet assay is

based on the principle that DNA fragments formed via DNA damage can be detected after agarose gel electrophoresis and fluorescent staining (Singh et al., 1988). Moreover, the use of different pH conditions during the cell lysis step allows the detection of different types of DNA damage, including single- and double-strand breaks and alkali-labile sites (Kohn, 1991). The comet assay was performed as follows. In brief, HEK/UGT cells were seeded in 24-well plates 24 h before treatment. Cells were treated for 24 h with 0.5% (v/v) FBS-supplemented DMEM containing either vehicle (0.1% DMSO), 1 mM naproxen, 0.1 mM diclofenac, 1 mM ketoprofen or 1 mM ibuprofen. Microscope slides were prepared by immersion in 0.5% (w/v) normal melting agarose. One volume of cell suspension (100  $\mu$ l, containing approximately  $4 \times 10^5$  cells) was mixed with 9 volumes of 0.7% (w/v) low-melting point agarose maintained at 37°C in a water bath, after which 100  $\mu$ l of the diluted suspension was layered on a precoated slide. The slide was immediately covered with a coverslip and incubated at 4°C to solidify the agarose. After the slides were coated with a third layer of 0.7% (w/v) low-melting point agarose at 4°C for 20 min, the embedded cells were immersed for 1 h at 4°C in cold lysis buffer [2.5 M NaCl, 1% (w/v) sodium *N*-lauroylsarcosinate, 100 mM disodium EDTA, and 10 mM Tris base, pH 10] supplemented with 1% (v/v) Triton X-100 and 10% (v/v) DMSO. The slides were placed in a horizontal electrophoresis assembly containing fresh electrophoresis buffer (100 mM NaOH and 10 mM disodium EDTA). To allow DNA unfolding and unwinding, we left the slides in the buffer for 30 min before electrophoresis. After electrophoretic resolution (300 mA for 20 min) using a recirculating horizontal tank (BE-560; Biocraft, Tokyo, Japan), the slides were washed in neutralizing buffer (0.4 M Tris-HCl, pH 7.5) twice for 5 min each and then were stained with ethidium bromide and examined in a fluorescent microscope (BZ-9000; Keyence Corporation, Osaka, Japan). The resulting photographs of fluorescently labeled comets were scored on the basis of the tail extent moment using CometAnalyzer 1.5 (Youworks Corporation, Tokyo, Japan).

The comet moment was typically determined for 150 to 180 cells per treatment on more than three separate experimental days. Data are presented as medians  $\pm$  interquartile range.

**Statistical Analyses.** Data are expressed as the mean  $\pm$  S.D. of three independent determinations. Statistical significance of the cytotoxicity data were determined by a two-tailed Student's *t* test, and comet data were analyzed using a two-tailed nonparametric Mann-Whitney's *U* test (GraphPad Software Inc., San Diego, CA). *P* < 0.05 was considered statistically significant.

## Results

**UGT1A3 and UGT1A4 in HEK293 Cells: Expression Levels and Enzyme Activities.** To establish the stable cell line expressing UGT1A3, five clones were isolated. Immunoblot analysis revealed that the expression levels of UGT varied among the clones and the clones with the highest UGT1A protein levels were selected (data not shown). The HEK293 expression systems of UGT1A3 (HEK/




FIG. 1. SDS-PAGE and immunoblot analyses of human UGT1As proteins. Total cell homogenates from HEK/MOCK, HEK/UGT1A3, or HEK/UGT1A4 cells were prepared. The samples (10  $\mu$ g) were subjected to 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane was probed with an anti-human UGT1A antibody. The UGT1A mRNA levels were corrected with the GAPDH mRNA levels.

TABLE 1

Kinetic parameters for 4-MU *O*-glucuronidation by UGT1A3 and imipramine *N*-glucuronidation by UGT1A4 expressed in HEK293 cells

Data represent the mean  $\pm$  S.D. ( $n = 3$ ).

UGT Isoform	Glucuronidation	$K_m$	$V_{max}$
		mM	pmol/(min $\cdot$ mg protein)
UGT1A3	4-MU <i>O</i> -glucuronidation	0.3 $\pm$ 0.0	640.4 $\pm$ 92.1
UGT1A4	Imipramine <i>N</i> -glucuronidation	1.1 $\pm$ 0.2	240.9 $\pm$ 02.9

UGT1A3) or UGT1A4 (HEK/UGT1A4) showed a double band of approximately 54/57 kDa and a single band of approximately 56 kDa, respectively (Fig. 1). As Riedmaier et al. (2010) reported that not only UGT1A3 in human liver microsomes but also recombinant UGT1A3 appeared as a double band of approximately 54/57 kDa, the expression pattern of UGT1A3 was consistent with that of our established UGT1A3. These data indicated that the expressions of UGT1A3 and UGT1A4 were at comparable levels.

After preparation of the total cell homogenate of UGT1A3, the 4-MU *O*-glucuronidation activity was investigated. In our previous study (Fujiwara et al., 2007b), we demonstrated that the total cell homogenate of UGT1A4 could catalyze the *N*-glucuronidation of imipramine. As seen in Table 1, HEK/UGT1A3 and HEK/UGT1A4 showed enzyme activity for each substrate. These data indicated that the enzyme activity of UGT1A3 and UGT1A4 was sufficiently high.

**Quantification of AG in HEK/UGT Cells.** To investigate the AG formation of each stable cell line, the AG in the cell fraction and the cultured medium was quantified at 6, 12, and 24 h after treatment with the NSAIDs. The AG was not detected in HEK/MOCK and HEK/UGT1A4 cells by LC-MS/MS analysis, whereas it was detected in HEK/UGT1A3 cells (Fig. 2). The AG of naproxen, diclofenac, ketoprofen, and ibuprofen in the cell fraction at 24 h was 4.5  $\pm$  0.8, 3.8  $\pm$  0.4, 0.2  $\pm$  0.1, and 7.2  $\pm$  1.2 pmol/2  $\times$  10<sup>5</sup> cells, respectively, and that in the cultured medium was 137.0  $\pm$  0.8, 104.0  $\pm$  13.1, 6.3  $\pm$  0.7, and 114.7  $\pm$  2.2 pmol/ml, respectively (Supplemental Tables 1-1 and 1-2). Compared with the AG in the cell fraction of HEK/UGT1A3, the AG in the cultured medium was increased in a time-dependent manner. The AG formed in NSAID-treated cells was not accumulated and effectively distributed in the medium.

**Cytotoxicity of NSAIDs in HEK/UGT Cells.** To investigate the cytotoxicity of the AGs of the NSAIDs, MTT, ATP, and LDH release assays were performed using HEK/UGT cells. In the MTT and ATP assays (Fig. 3), cell viability was decreased time dependently after treatment with the NSAIDs. However, there was no difference in the cell viability of HEK/UGT1A3 cells, which produced the AG, compared with that of HEK/MOCK and/or HEK/UGT1A4 cells. LDH leakage into the cultured medium was also assessed for 6-, 12-, and 24-h incubations. In each HEK/UGT cell line, none of the NSAIDs demonstrated LDH leakage that exceeded 5.4% of the total cell LDH levels (Supplemental Fig. 1). These results indicated that no cytotoxicity due to the AG formation from the NSAIDs was detected in HEK/UGT cells.




Fig. 2. Time-dependent changes of AG formation in NSAID-treated HEK/UGT1A3 cells. HEK/UGT1A3 cells ( $2 \times 10^5$  cells/ml/well) were incubated with naproxen (1 mM), diclofenac (0.1 mM), ketoprofen (1 mM), or ibuprofen (1 mM) for 6, 12, and 24 h. The cell fraction (picomoles per  $2 \times 10^5$  cells) and the cultured medium (picomoles per milliliter) were measured by LC-MS/MS.  $\circ$ , cell fraction;  $\bullet$ , cultured medium. Each point represents the mean  $\pm$  S.D. of triplicate determinations.

In addition, to investigate whether the other substrates affected the cytotoxicity, we used an MTT assay of HEK/UGT cells exposed to other carboxylic acid drugs such as clofibrac acid (1 mM), gemfibrozil (1 mM), salicylic acid (1 mM), and zomepirac (0.1 mM) at 24 h. The cell viability of HEK/UGT1A3 cells was not significantly decreased compared with that of HEK/UGT1A4 cells (Supplemental Fig. 2).

**Quantification of AG in Human Hepatocytes.** To investigate the inhibition effect of (-)-borneol on the formation of AG in NSAID-treated human hepatocytes, the AG in the cell fraction and the cultured medium was quantified. Without (-)-borneol treatment, the AG of naproxen, diclofenac, ketoprofen, and ibuprofen formed in the cell fraction at 6 h was 33.6  $\pm$  1.0, 59.6  $\pm$  1.1, 6.8  $\pm$  0.5, and 27.7  $\pm$  1.6 pmol/2  $\times$  10<sup>5</sup> cells, respectively, and that formed in the cultured medium was 1323.9  $\pm$  44.3, 2816.1  $\pm$  63.5, 436.8  $\pm$  8.0, and 1156.7  $\pm$  21.9 pmol/ml, respectively (Fig. 4). On the other hand, with (-)-borneol treatment, the AG of naproxen, diclofenac, ketoprofen, and ibuprofen formed in the cell fraction at 6 h was 10.3  $\pm$  0.4, 15.1  $\pm$  1.3, 1.7  $\pm$  0.1, and 3.5  $\pm$  0.3 pmol/2  $\times$  10<sup>5</sup> cells, respectively, and that formed in the cultured medium was 393.7  $\pm$  13.7, 610.5  $\pm$  29.7, 54.9  $\pm$  0.8, and 126.5  $\pm$  10.6 pmol/ml, respectively (Fig. 4). Therefore, the AG formed in NSAID-treated human hepatocytes was decreased to one-third to one-ninth by (-)-borneol treatment.

**Cytotoxicity of NSAIDs in Human Hepatocytes.** We confirmed the inhibition effect of (-)-borneol on the AG formation of the NSAIDs in human hepatocytes. To investigate the effect of AG on the cytotoxicity in human hepatocytes, ATP and MTT assays were performed. In the ATP assay (Fig. 5A), the cell viability without (-)-borneol treatment was significantly decreased in the presence of the NSAIDs except ketoprofen compared with the nontreated control. If the AG showed cytotoxicity, the cell viability would be restored by (-)-borneol treatment. The cell viability with (-)-borneol treatment was further decreased, even though the AG formed in human hepatocytes was decreased. Likewise, MTT assay revealed that the cell viability was significantly decreased in the presence of naproxen (Fig. 5B). (-)-Borneol decreased the cell viability in the presence of diclofenac or ibuprofen. If the AG showed cytotoxicity, the cell viability would be restored by (-)-borneol treatment. However, (-)-borneol unexpectedly decreased the cell viability. To investigate whether the cytotoxicity is due to increased contents of the parent drugs in the cell fraction, we quantified the parent drugs using LC-MS/MS analysis. As a result, the contents of the parent drugs with (-)-borneol treatment were significantly higher than those without (-)-borneol treatment (Fig. 5C). These results indicated that the decreased cell viability of human hepatocytes with (-)-borneol treatment might be due to the increased contents of the parent drugs in the cell fraction. Therefore, AG formed in NSAID-treated human hepatocytes showed no cytotoxicity.

**Comet Assay.** To investigate the possibility that the AG formed in NSAID-treated HEK/UGT cells caused secondary genotoxicity by nicking DNA, the comet assay was conducted after the 24-h treatment. The scores of the tail moments of NSAID-treated HEK/UGT




FIG. 3. Time-dependent changes of cell viability assessed by MTT and ATP assays in NSAID-treated HEK/UGT cells. A, MTT assay. B, ATP assay. HEK/UGT cells ( $2 \times 10^4$  cells/0.1 ml/well) were incubated with naproxen (1 mM), diclofenac (0.1 mM), ketoprofen (1 mM), and ibuprofen (1 mM) for 6, 12, and 24 h.  $\circ$ , MOCK;  $\blacksquare$ , UGT1A3;  $\blacktriangle$ , UGT1A4. Each point represents the mean  $\pm$  S.D. of triplicate determinations.

cells are shown in Fig. 6. Cells exposed to the NSAIDs showed hardly any DNA strand breaks compared with the controls. Methylmethane sulfonate at 0.1 mM, as a positive control, caused a significant increase in DNA migration ( $P < 0.001$ ) compared with the solvent control (DMSO). As shown in Fig. 6B, no drugs significantly increased the DNA migration in HEK/UGT1A3 cells, even though AG was produced in the cells. No genotoxicity owing to the AG formation from the NSAIDs could be detected in the present study.

**Discussion**

There is increasing evidence that the formation of drug-protein adducts is involved in idiosyncratic reactions. However, direct mechanism-based evidence linking the toxicity to the formation of drug-protein adducts is lacking. We focused in this study on the toxicity due to cell dysfunction by acyl glucuronide formation. Therefore, we investigated whether the acyl glucuronide of NSAIDs represents cytotoxicity directly. In the toxicological assessment of AG in vitro, exposure

of the cells to the hydrophilicity of AG must be taken into account, because it is possible that exposure to the AG from outside the cells could result in poor absorption. Therefore, to clarify the toxicity of AG, the cytotoxicity and genotoxicity of the AG formed in NSAID-treated HEK/UGT cells and human hepatocytes were evaluated at high concentrations, but there was no severe cytotoxicity from the parent drugs per se. For example, diclofenac caused low cell viability (approximately 20% of MOCK cells) at 1 mM (data not shown). Therefore, we examined diclofenac toxicity at 0.1 mM. On the other hand, naproxen, ibuprofen, and ketoprofen were examined at 1 mM.




FIG. 4. Effect of (-)-borneol treatment on AG formation in NSAID-treated human hepatocytes. Human hepatocytes ( $2 \times 10^5$  cells/ml/well) treated with 1 mM (-)-borneol for 30 min were incubated with naproxen (1 mM) (A), diclofenac (0.1 mM) (B), ketoprofen (1 mM) (C), or ibuprofen (1 mM) (D) for 6 h. The cell fraction and the cultured medium were measured by LC-MS/MS analysis. Each point represents the mean  $\pm$  S.D. of triplicate determinations. \*\*\*,  $P < 0.001$  compared with without (-)-borneol treatment (control).




FIG. 5. Effect of (-)-borneol treatment on cell viability assessed by ATP (A) or MTT (B) assays and on contents of parent NSAIDs in the cell fraction (C) of human hepatocytes. The human hepatocytes ( $2 \times 10^4$  cells/0.1 ml/well) treated with 1 mM (-)-borneol for 30 min were incubated with naproxen (1 mM), diclofenac (0.1 mM), ketoprofen (1 mM), or ibuprofen (1 mM) for 6 h.  $\square$ , without (-)-borneol treatment;  $\blacksquare$ , with (-)-borneol treatment. Each column represents the mean  $\pm$  S.D. of triplicate determinations. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ , compared with without (-)-borneol treatment. #,  $P < 0.05$ ; ##,  $P < 0.01$ ; ###,  $P < 0.001$ , compared with without NSAID treatment.




FIG. 6. DNA damage measured by the comet assay in HEK/MOCK (A), HEK/UGT1A3 (B), or HEK/UGT1A4 (C) cells. HEK/UGT cells ( $2 \times 10^5$  cells/ml/well) were incubated with naproxen (1 mM), diclofenac (0.1 mM), ketoprofen (1 mM), ibuprofen (1 mM), and methylmethane sulfonate (MMS) (0.1 mM, as a positive control) for 24 h. Results are shown as median ( $\pm$  interquartile range) tail moment calculated from 30 to 60 comets scored per slide, in more than three separate experiments (total 150–180 comets).  $\circ$ , outliers. \*\*\*,  $P < 0.001$  compared with control (DMSO vehicle) incubations.

HEK/UGT1A3 cells were constructed to investigate the cytotoxicity of AG. HEK/UGT1A4 cells were also used as a reference for HEK/UGT1A3 cells. HEK/UGT1A4 cells have the characteristics of high amino acid homology and different catalytic properties compared with HEK/UGT1A3 cells. Moreover, HEK/UGT1A4 cells could reflect the cytotoxicity of AG more accurately than HEK/MOCK cells (Fig. 1). After exposure to the NSAIDs for 24 h, AG formation was only detected in HEK/UGT1A3 cells in a time-dependent manner (Fig. 2). However, there was no difference in the cytotoxicity to HEK/UGT1A3 cells compared with that to HEK/UGT1A4 cells, even though HEK/UGT1A3 cells could produce AG (Fig. 3; Supplemental Fig. 1). Although the cytotoxicity of other carboxylic acid drugs (i.e., clofibrac acid, gemfibrozil, salicylic acid, or zomepirac) in HEK/UGT cells was investigated, the cell viability of HEK/UGT1A3 cells was not significantly decreased compared with that of HEK/UGT1A4 cells (Supplemental Fig. 2). Furthermore, the cytotoxicity of other carboxylic acid drugs such as acetylsalicylic acid, flurbiprofen, indomethacin, niflumic acid, mefenamic acid, sulindac, bezafibrate, furosemide, probenecid, or mycophenolic acid at 1 mM was investigated by using the MTT assay, and the cell viability of HEK/UGT1A3 cells was not significantly decreased (data not shown). Therefore, no cytotoxicity of AG was detected even when other carboxylic acid drugs were selected. In general, it has been thought that protein and/or DNA adduct formation in response to AG is a causal factor for toxicity. Therefore, we may not be able to exclude the possibility of increased cytotoxicity after long-term exposure to carboxylic acid drugs. To address this issue, the cytotoxicity was investigated by using the MTT assay after exposure to the drugs (naproxen, ketoprofen, ibuprofen, clofibrac acid, gemfibrozil, and salicylic acid at 1 mM and diclofenac and zomepirac at 0.1 mM) for up to 72 h. However, there was no significant difference in the cell viability of the HEK/UGT cells (data not shown).

HEK293 cells have been noted to lack many uptake and efflux transporters that are normally expressed on human hepatocytes. For example, HEK293 cells do not express organic anion-transporting polypeptide 2 or 8 (Hirano et al., 2004), so that the uptake of carboxylic acid drugs may be lower than that in human hepatocytes. Likewise, HEK293 cells do not express multidrug resistance-associated protein 2 (Hagmann et al., 1999) or multidrug resistance-associated protein 3 (Zeng et al., 2000), so that the efflux of intracellularly generated AG may be lower than that in human hepatocytes. Therefore, the cytotoxicity of AG was investigated by using human hepatocytes that might reflect more closely AG formation in vivo. The AG formation in human hepatocytes was much higher than that in HEK/UGT1A3 cells. In particular, the AG in the cell fraction of human hepatocytes at 6 h of treatment was approximately 6- to 30-fold that in the cell fraction of HEK/UGT1A3 cells (Figs. 2 and 4). These results suggested that other UGT isoforms (i.e., UGT1A9 and UGT2B7) catalyzing the glucuronidation of the carboxylic acid drugs and/or the transporters involved in the AG formation might be expressed in human hepatocytes. Although the AG formed in NSAID-

treated human hepatocytes was decreased by (–)-borneol treatment, the cytotoxicity was increased. The LC-MS/MS analysis indicated that the content of the parent drugs in the cell fraction of human hepatocytes with (–)-borneol treatment was significantly higher than that without (–)-borneol treatment (Fig. 5C). These results suggested that the formation of AG in human hepatocytes might represent a detoxification process.

The comet assay is a unique assay method for assessing the genotoxicity of AG (Sallustio et al., 1997, 2006; Southwood et al., 2007). Thus, we investigated genotoxicity using the comet assay. The results showed that the tail moments of the DNA migration were not significantly different in the HEK/UGT cell lines, even though HEK/UGT1A3 cells produced AG in the presence of the NSAIDs. Therefore, the AG formation from the NSAIDs is not involved in genotoxicity in vitro. In a recent report, Brambilla and Martelli (2009) described the genotoxicity and carcinogenicity of many NSAIDs. According to their report, naproxen, diclofenac, ketoprofen, and ibuprofen gave negative responses in reverse mutation (Ames) tests with *Salmonella typhimurium* and in a long-term carcinogenesis assay using rats and mice. Our results showing a lack of genotoxicity for all four NSAIDs by the comet assay are in accordance with this report. On the other hand, clofibrac acid (1 mM), which produced no AG metabolites, gave significantly positive results for genotoxicity by the comet assay using HEK/UGT1A3 cells at 24 h of treatment (data not shown). This result supported the previous report of Southwood et al. (2007). As described in this report, fibrate hypolipidemic agents such as clofibrac acid are nongenotoxic (Ashby et al., 1994). Therefore, one should be careful in interpreting the results of the comet assay.

Among the NSAIDs containing carboxylic acid drugs, diclofenac AG is one of the most studied for its related toxicity. Diclofenac AG is excreted into bile and transported to the small intestine where it can produce erosions and ulcers in a dose-dependent manner (Seitz and Boelsterli, 1998). In a recent article, Lagas et al. (2010) reported that *Mrp2/Mrp3/Bcrp1*<sup>-/-</sup> mice have markedly elevated levels of diclofenac AG in their liver and display acute, albeit mild, hepatotoxicity. As for the metabolic activation, it is well known that diclofenac is converted to 4'-hydroxydiclofenac and 5-hydroxydiclofenac via direct hydroxylation and that these two metabolites are further oxidized to form benzoquinone imine intermediates by human CYP2C9 and CYP3A4, respectively (Tang et al., 1999). Quinone imines are electrophiles that have been generally implicated in redox cycling and in producing oxidative stress and can undergo covalent binding with nonprotein or protein sulfhydryl groups because of their thiol reactivity (Boelsterli, 2003). Given the toxicity of diclofenac, it seemed to be important to evaluate not only the AG but also the quinone imines of diclofenac.

In conclusion, we investigated the relationship between cytotoxicity and AG formation by NSAIDs (naproxen, diclofenac, ketoprofen, and ibuprofen) in HEK/UGT cells and human hepatocytes and also the genotoxicity of the AG from NSAIDs in HEK/UGT cells. However,

no cytotoxicity or genotoxicity due to the AG formed in the cells was found in the present study. Therefore, because AG appeared not to be a causal factor of the toxicity in vitro, additional work addressing a possible immune-mediated toxicity will be needed to clarify the toxicity of AG. This study provides new insight into the evaluation of acyl glucuronide toxicity in drug development.

#### Acknowledgments

We acknowledge Dr. Tetsushi Watanabe (Kyoto Pharmaceutical University) for technical teaching and discussion about the comet assay and Brent Bell for reviewing the manuscript.

#### Authorship Contributions

*Participated in research design:* Koga, Nakajima, and Yokoi.

*Conducted experiments:* Koga.

*Contributed new reagents or analytic tools:* Koga and Fujiwara.

*Performed data analysis:* Koga.

*Wrote or contributed to the writing of the manuscript:* Koga and Yokoi.

#### References

- Ashby J, Brady A, Elcombe CR, Elliot BM, Ishamael J, Odum J, Tugwood JD, Kettle S, and Purchase IFH (1994) Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. *Hum Exp Toxicol* **13** (Suppl 2):S1-S117.
- Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. *Chem Biol Interact* **145**:117-137.
- Banks AT, Zimmerman HJ, Ishak KG, and Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. *Hepatology* **22**:820-827.
- Boelsterli UA (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. *Toxicol Appl Pharmacol* **192**:307-322.
- Boelsterli UA, Zimmerman HJ, and Kretz-Rommel A (1995) Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. *Crit Rev Toxicol* **25**:207-235.
- Brambilla G and Martelli A (2009) Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics. *Pharmacol Res* **60**:1-17.
- Castillo M and Smith PC (1995) Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. *Drug Metab Dispos* **23**:566-572.
- Cuthbert MF (1974) Adverse reactions to non-steroidal antirheumatic drugs. *Curr Med Res Opin* **2**:600-610.
- Foster RT, Jamali F, Russell AS, and Alballa SR (1988) Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses. *J Pharm Sci* **77**:191-195.
- Fujiwara R, Nakajima M, Yamanaka H, Nakamura A, Katoh M, Ikushiro S, Sakaki T, and Yokoi T (2007a) Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. *Drug Metab Dispos* **35**:747-757.
- Fujiwara R, Nakajima M, Yamanaka H, Katoh M, and Yokoi T (2007b) Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. *Drug Metab Dispos* **35**:1781-1787.
- Hagmann W, Nies AT, König J, Frey M, Zentgraf H, and Keppler D (1999) Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. *Eur J Biochem* **265**:281-289.
- Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. *J Pharmacol Exp Ther* **311**:139-146.
- Kohn KW (1991) Principles and practice of DNA filter elution. *Pharmacol Ther* **49**:55-77.
- Kubota T, Lewis BC, Elliot DJ, Mackenzie PI, and Miners JO (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. *Mol Pharmacol* **72**:1054-1062.
- Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC, and Baillie TA (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. *J Pharmacol Exp Ther* **303**:969-978.
- Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac is dependent on multiple ATP-binding cassette efflux transporters. *Mol Pharmacol* **77**:687-694.
- Nakajima M, Koga T, Sakai H, Yamanaka H, Fujiwara R, and Yokoi T (2010) N-Glycosylation plays a role in protein folding of human UGT1A9. *Biochem Pharmacol* **79**:1165-1172.
- Nishiyama T, Izawa T, Usami M, Ohnuma T, Ogura K, and Hiratsuka A (2010) Cooperation of NAD(P)H:quinone oxidoreductase 1 and UDP-glucuronosyltransferases reduces menadione cytotoxicity in HEK293 cells. *Biochem Biophys Res Commun* **394**:459-463.
- Pirmohamed M, Madden S, and Park BK (1996) Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. *Clin Pharmacokinet* **31**:215-230.
- Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, and Zanger UM (2010) UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. *Clin Pharmacol Ther* **87**:65-73.
- Riley TR 3rd and Smith JP (1998) Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. *Am J Gastroenterol* **93**:1563-1565.
- Ritter JK (2000) Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. *Chem Biol Interact* **129**:171-193.
- Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, and King C (2004) Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. *Arch Biochem Biophys* **424**:219-225.
- Sallustio BC, Degraaf YC, Weekley JS, and Burcham PC (2006) Bioactivation of carboxylic acid compounds by UDP-glucuronosyltransferases to DNA-damaging intermediates: role of glyco-oxidation and oxidative stress in genotoxicity. *Chem Res Toxicol* **19**:683-691.
- Sallustio BC, Harkin LA, Mann MC, Krivickas SJ, and Burcham PC (1997) Genotoxicity of acyl glucuronide metabolites formed from clofibrate and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? *Toxicol Appl Pharmacol* **147**:459-464.
- Seitz S and Boelsterli UA (1998) Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. *Gastroenterology* **115**:1476-1482.
- Shipkova M, Armstrong VW, Oellerich M, and Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. *Ther Drug Monit* **25**:1-16.
- Singh NP, McCoy MT, Tice RR, and Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. *Exp Cell Res* **175**:184-191.
- Southwood HT, DeGraaf YC, Mackenzie PI, Miners JO, Burcham PC, and Sallustio BC (2007) Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. *Chem Res Toxicol* **20**:1520-1527.
- Tang W, Stearns RA, Wang RW, Chiu SH, and Baillie TA (1999) Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. *Chem Res Toxicol* **12**:192-199.
- Vree TB, Van Den Biggelaar-Martea M, Verwey-Van Wissen CP, Vree ML, and Guelen PJ (1993) The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. *Br J Clin Pharmacol* **35**:467-472.
- Wade LT, Kenna JG, and Caldwell J (1997) Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. *Chem Res Toxicol* **10**:546-555.
- Walker AM (1997) Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. *Arthritis Rheum* **40**:201-208.
- Zeng H, Liu G, Rea PA, and Kruh GD (2000) Transport of amphipathic anions by human multidrug resistance protein 3. *Cancer Res* **60**:4779-4784.

---

**Address correspondence to:** Dr. Yokoi Tsuyoshi, Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakumamachi, Kanazawa 920-1192, Japan. E-mail: tyokoi@kenroku.kanazawa-u.ac.jp

---

**Supplemental Data to DMD/2010/035600:**

**Article title:** Toxicological evaluation of acyl glucuronides of NSAIDs using HEK293 cells stably expressing human UGT and human hepatocytes

**Authors:** Toshihisa Koga, Ryoichi Fujiwara, Miki Nakajima, and Tsuyoshi Yokoi

**Journal title:** Drug Metabolism and Disposition

**Supplementary Table 1-1**

Quantification of AG metabolites in cell fraction of NSAID-treated HEK/UGT cells.

Treatment time (h)	UGT isoform	Naproxen -AG	Diclofenac -AG	Ketoprofen -AG	Ibuprofen -AG
6	MOCK	ND	ND	ND	ND
	UGT1A3	5.0 ± 1.6	1.8 ± 0.0	0.7 ± 0.1	4.5 ± 0.6
	UGT1A4	ND	ND	ND	ND
12	MOCK	ND	ND	ND	ND
	UGT1A3	4.3 ± 0.8	2.2 ± 0.3	0.4 ± 0.0	5.6 ± 1.1
	UGT1A4	ND	ND	ND	ND
24	MOCK	ND	ND	ND	ND
	UGT1A3	4.5 ± 0.8	3.8 ± 0.4	0.2 ± 0.1	7.2 ± 1.2
	UGT1A4	ND	ND	ND	ND

AG: Acyl glucuronide

ND: Not detected, Detection limit: 0.1 pmol/2 x 10<sup>5</sup> cells

Concentration of NSAIDs; 1 mM (Naproxen, Ketoprofen, Ibuprofen), 0.1 mM (Diclofenac)

Data represent the mean ± SD (n=3).



**Supplementary Table 1-2**

Quantification of AG metabolites in cultured medium of NSAID-treated HEK/UGT cells.


Treatment time (h)	UGT isoform	Naproxen -AG	Diclofenac -AG	Ketoprofen -AG	Ibuprofen -AG
		(pmol/mL)			
6	MOCK	ND	ND	ND	ND
	UGT1A3	38.6 ± 2.2	9.0 ± 00.9	4.5 ± 0.2	32.0 ± 0.2
	UGT1A4	ND	ND	ND	ND
12	MOCK	ND	ND	ND	ND
	UGT1A3	78.7 ± 1.0	37.4 ± 02.3	8.3 ± 1.6	59.0 ± 3.8
	UGT1A4	ND	ND	ND	ND
24	MOCK	ND	ND	ND	ND
	UGT1A3	137.0 ± 0.8	104.0 ± 13.1	6.3 ± 0.7	114.7 ± 2.2
	UGT1A4	ND	ND	ND	ND

AG: Acyl glucuronide

ND: Not detected, Detection limit: 1 pmol/mL


Concentration of NSAIDs; 1 mM (Naproxen, Ketoprofen, Ibuprofen), 0.1 mM (Diclofenac)

Data represent the mean ± SD (n=3).



**Supplementary Figure 1:**

Time-dependent changes of membrane integrity assessed by LDH release assay in NSAID-treated HEK/UGT cells. HEK/UGT cells ( $2 \times 10^4$  cells/0.1 mL/well) were incubated with naproxen (1 mM), diclofenac (0.1 mM), ketoprofen (1 mM), or ibuprofen (1 mM) for 6, 12, and 24 h. (○) MOCK; (■) UGT1A3; (▲) UGT1A4. Each column represents mean  $\pm$  SD of triplicate determinations.



**Supplementary Figure 2:**

Cell viability assessed by MTT assays in drug-treated HEK/UGT cells. HEK/UGT cells ( $2 \times 10^4$  cells/0.1 mL/well) were incubated with clofibrinic acid (1 mM), gemfibrozil (1 mM), salicylic acid (1 mM), or zomepirac (0.1 mM) for 24 h. The open columns represent HEK/MOCK, the closed columns represent HEK/UGT1A3, and the hatched columns represent HEK/UGT1A4 cells. Each column represents mean  $\pm$  SD of triplicate determinations. \*\*\* $P < 0.001$  compared with HEK/MOCK cells.



## IL-4 mediates dicloxacillin-induced liver injury in mice

Satonori Higuchi<sup>a</sup>, Masanori Kobayashi<sup>a</sup>, Yukitaka Yoshikawa<sup>a</sup>, Koichi Tsuneyama<sup>b</sup>,  
Tatsuki Fukami<sup>a</sup>, Miki Nakajima<sup>a</sup>, Tsuyoshi Yokoi<sup>a,\*</sup>

<sup>a</sup> Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan

<sup>b</sup> Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, Sugitani, 930-0194 Toyama, Japan

### ARTICLE INFO

#### Article history:

Received 18 September 2010

Received in revised form

10 November 2010

Accepted 11 November 2010

Available online 19 November 2010

#### Keywords:

13,14-Dihydro-15-keto-prostaglandin D<sub>2</sub>

Drug-induced liver injury

IL-4

### ABSTRACT

Drug-induced liver injury (DILI) is a major problem in drug development and clinical drug therapy. In most cases, the mechanisms are still unknown. It is difficult to predict DILI in humans due to the lack of experimental animal models. Dicloxacillin, penicillinase-sensitive penicillin, rarely causes cholestatic or mixed liver injury, and there is some evidence for immunoallergic idiosyncratic reaction in human. In this study, we investigated the mechanisms of dicloxacillin-induced liver injury. Plasma ALT and total-bilirubin (T-Bil) levels were significantly increased in dicloxacillin-administered (600 mg/kg, i.p.) mice. Dicloxacillin administration induced Th2 (helper T cells)-mediated factors and increased the plasma interleukin (IL)-4 level. Neutralization of IL-4 suppressed the hepatotoxicity of dicloxacillin, and recombinant mouse IL-4 administration (0.5 or 2.0 μg/mouse, i.p.) exacerbated it. Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) is a cognate receptor for prostaglandin (PG) D<sub>2</sub>, and is suggested to be involved in Th2-dependent allergic inflammation. We investigated the effect of 13,14-Dihydro-15-keto-PGD<sub>2</sub> (DK-PGD<sub>2</sub>; 10 μg/mouse, i.p.) administration on dicloxacillin-induced liver injury. DK-PGD<sub>2</sub>/dicloxacillin coadministration resulted in a significant increase of alanine aminotransferases and a remarkable increase of macrophage inflammatory protein 2 expression. In conclusion, to the best of our knowledge, this is the first report to demonstrate that dicloxacillin-induced liver injury is mediated by a Th2-type immune reaction and exacerbated by DK-PGD<sub>2</sub>.

© 2010 Elsevier Ireland Ltd. All rights reserved.

### 1. Introduction

Drug-induced liver injury (DILI) is the most frequent reason for the withdrawal of an approved drug from the market and for failures in drug development in pharmaceutical companies. Because of DILI, several drugs have been removed from the pharmaceutical market, including bromfenac, ebrotidine, and troglitazone (Holt and Ju, 2006). In most cases, the mechanisms of DILI are unknown and predictive experimental animal models are lacking.

Adverse effects of antibiotics are variable and can induce phlebitis, hypersensitivity reactions, changes in microbial flora, adverse interactions with other drugs as well as liver injury (Stein, 2005). It has been reported that there are many case reports of DILI due to antibiotics administration (Bjornsson and Olsson, 2005), however there are a few reports of pathological investigations. Dicloxacillin and penicillinase-sensitive penicillin rarely cause liver injury and there is some evidence for an immunoallergic idiosyncratic reaction. Dicloxacillin induced cholestasis with a moderate inflammatory reaction, allergic symptoms and infiltration of mononuclear cells, such as neutrophils and eosinophils,

were demonstrated in many cases (Olsson et al., 1992). Allergic symptoms and eosinophilia are generally induced by Th2 cytokines (Kay, 2001). From these lines of evidences, we hypothesized that Th2 factors might involve in dicloxacillin-induced liver injury.

T cell-mediated immune responses play pivotal roles in the pathogenesis of a variety of human liver disorders (Kita et al., 2001; Heneghan and McFarlane, 2002; Holt and Ju, 2006). The action of T cells in the liver is mediated through the release of a variety of cytokines, which target liver cells and immune cells by activating multiple signaling cascades, including the signal transducers and activators of transcription factor (STAT) family members (Leonard and O'Shea, 1998). STAT6 is specifically activated by interleukin (IL)-4, which plays important roles in Th2 differentiation, tissue adhesion, and inflammation (Jaruga et al., 2003; Nelms et al., 1999). Th cells are subdivided into Th1, Th2, and Th17 subsets by their unique production of cytokines and characteristic transcription factors. Th1 cells require "T-box expressed in T cells" (T-bet) and secrete interferon (IFN)-γ. In contrast, Th2 cells require GATA-binding domain-3 (GATA-3) and produce IL-4, IL-5 and IL-13. Retinoid-related orphan receptor γt (ROR-γt) is indispensable for the differentiation of Th17 cells which mainly secrete IL-17 and IL-22 (Kidd, 2003; Steinman, 2007).

Th2-type cytokines such as IL-4 and IL-5 influence a wide range of events associated with allergic inflammation. IL-4 stimulates the

\* Corresponding author. Tel./fax: +81 76 234 4407.

E-mail address: [tyokoi@kenroku.kanazawa-u.ac.jp](mailto:tyokoi@kenroku.kanazawa-u.ac.jp) (T. Yokoi).

production of IgE and promotes the development of mast cells. IL-5 is involved in the development of eosinophils (Kay, 2001). In concanavalin (Con) A-mediated hepatitis, a widely accepted mouse model for studying T cell-mediated liver injury, IL-4 stimulates the secretion of Eotaxin-1 and enhances IL-5 production resulting in the attraction of neutrophils and eosinophils into the liver which leads to hepatitis (Jaruga et al., 2003).

Prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) is implicated in various allergic inflammatory diseases, such as atopic dermatitis, allergic asthma, and airway inflammation. It has been reported that PGD<sub>2</sub> has protective roles in acetaminophen-induced liver injury and 15-deoxy PGJ<sub>2</sub>, which is a metabolite of PGD<sub>2</sub>, enhances allyl alcohol-induced hepatotoxicity (Reilly et al., 2001; Maddox et al., 2004). PGD<sub>2</sub> elicits biological responses by activating two receptors, the D-prostanoid receptor (DP) and the chemoattractant receptor homologous-molecule expressed on T-helper-type-2 cells (CRTh2), which are linked to different signaling pathways. CRTh2 expresses in eosinophils, basophils, and Th2 cells, but not in hepatocytes or endothelial cells. The decrease in cAMP levels and mobilization of intracellular Ca<sup>2+</sup> mediated by CRTh2 activation leads to the chemotaxis of Th2 lymphocytes, eosinophils, and monocytes. 13,14-Dihydro-15-keto-prostaglandin D<sub>2</sub> (DK-PGD<sub>2</sub>) is a selective CRTh2 agonist that does not activate DP, as reviewed by Kostenis and Ulven (2006). CRTh2 activation plays a significant role in Th2-dependent neutrophil inflammation (Takeshita et al., 2004). In this study, we found that dicloxacillin-induced liver injury is mediated by IL-4 and exacerbated by DK-PGD<sub>2</sub> in mice.

## 2. Materials and methods

### 2.1. Chemicals

Dicloxacillin was purchased from Sigma (St. Louis, MO). RNAiso was from Nippon Gene (Tokyo, Japan). Fuji DRI-CHEM slides of GPT/ALT-P111 and TBIL-P111 to measure alanine aminotransferase (ALT) and total-bilirubin (T-Bil), respectively, were from FujiFilm (Tokyo, Japan). ReverTra Ace was from Toyobo (Tokyo, Japan). Random hexamer and SYBR Premix Ex Taq were from Takara (Osaka, Japan). All primers were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). 13,14-Dihydro-15-keto-prostaglandin D<sub>2</sub> (DK-PGD<sub>2</sub>) was purchased from Cayman Chemical (Denver, CO). Recombinant mouse IL-4 (rIL-4) was from Endogen (Cambridge, MA). Rabbit polyclonal antibody against myeloperoxidase (MPO) was from DAKO (Carpinteria, CA). Monoclonal anti-mouse IL-4 antibody was from U-Cytech Biosciences (Utrecht, Netherlands). Monoclonal rat IgG2a isotype, used as a control, from R&D Systems (Abingdon, UK). A Ready-SET-GO! Mouse Interleukin-4 (IL-4) enzyme-linked immunosorbent assay (ELISA) kit was from eBioscience (San Diego, CA). Other chemicals were of analytical or the highest grade commercially available.

### 2.2. Mouse models of dicloxacillin-induced liver injury

Female BALB/cCrSlc mice (6 weeks old) were obtained from SLC Japan (Hamamatsu, Japan). Mice were housed in a controlled environment (temperature 25 ± 1 °C, humidity 50 ± 10%, and 12 h light/12 h dark cycle) in the institutional animal facility with access to food and water *ad libitum*. Animals were acclimated before use for the experiments. Mice were administered intraperitoneally (i.p.) dicloxacillin (600 mg/kg, dissolved in saline) in a non-fasting condition. Six hours after dicloxacillin administration, the animals were sacrificed and the blood was collected from inferior vena cava, and liver from the biggest lobe. For measurement of the plasma IL-4 level, mice were sacrificed at 6 h after the dicloxacillin administration. A portion of each excised liver was fixed in 10% formalin neutral buffer solution and used for immunohistochemical staining. The degree of liver injury was assessed by hematoxylin-eosin (H&E) staining. Infiltration of mononuclear cells was assessed by immunostaining for MPO. Rabbit polyclonal antibody against MPO was used for immunohistochemical staining of liver as previously described (Kumada et al., 2004). Animal maintenance and treatment were conducted in accordance with the National Institutes of Health Guide for Animal Welfare of Japan, as approved by the Institutional Animal Care and Use Committee of Kanazawa University, Japan.

### 2.3. Real-time reverse transcription (RT)-PCR

RNA from the mouse liver was isolated using RNAiso according to the manufacturer's instructions. T-bet, GATA-3, ROR-γt, IFN-γ, IL-5, STAT1, STAT3, STAT6, Eotaxin-1, monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-2 (MIP-2) were quantified by real-time RT-PCR. The primer sequences used in this study are shown in Table 1. For the RT-process, total RNA (10 μg) and 150 ng random hexamer were mixed and incubated at 70 °C for 10 min. RNA solution was added to a reaction mixture containing 100 units of ReverTra Ace,

**Table 1**

Sequences of primers used for real-time RT-PCR analyses.

Gene		Sequences
mIL-5	FP	5'-AAA GAG ACC TTG ACA CAG CTG-3'
	RP	5'-CCA CGG ACA GTT TGA TTC TTC-3'
mIFN-γ	FP	5'-GGC CAT CAG CAA CAT AAG C-3'
	RP	5'-TGG ACC ACT CGG ATG AGC TCA-3'
mGATA-3	FP	5'-GGA GGA CTT CCC CAA GAG CA-3'
	RP	5'-CAT GCT GGA AGG GTG GTG A-3'
mT-bet	FP	5'-CAA GTG GGT GCA GTG TGG AAA G-3'
	RP	5'-TGG AGA GAC TGC AGG ACG ATC-3'
mROR-γt	FP	5'-ACC TCC ACT GCC AGC TGT GTG CTG TC-3'
	RP	5'-TCA TTT CTG CAC TTC TGC ATG TAG ACT GTC CC-3'
mSTAT-6	FP	5'-ATC TTC AAC GAC AAC AGC CTC A-3'
	RP	5'-GGA GAA GGC TAG TGA CAT ATT G-3'
mSTAT-1	FP	5'-GTT TCA GCT CTG CTC CAT AC-3'
	RP	5'-CTG CTG AAG CTC GAA CCA C-3'
mSTAT-3	FP	5'-TGC AGA GCA GGT ATC TTG AG-3'
	RP	5'-TGC TGC TTC TCT GTC ACT AC-3'
mEotaxin-1	FP	5'-TCC ACA GCG CTT CTA TTC CT-3'
	RP	5'-CTA TGG CTT TCA GGG TGC AT-3'
mMCP-1	FP	5'-TGT CAT GCT TCT GGG CCT G-3'
	RP	5'-CCT CTC TCT TGA GCT TGG TG-3'
mMIP-2	FP	5'-AAG TTT GCC TTG ACC CTG AAG-3'
	RP	5'-ATC AGG TAC GAT CCA GGC TTC-3'
mGAPDH	FP	5'-AAA TGG GGT GAG GCC GGT-3'
	RP	5'-ATT GCT GAC AAT CTT GAG TGA-3'

FP: forward primer, RP: reverse primer.

reaction buffer and 0.5 mM dNTPs in a final volume of 40 μl. The reaction mixture was incubated at 30 °C for 10 min, 42 °C for 1 h, and heated at 98 °C for 10 min to inactivate the enzyme. The real-time RT-PCR was performed using the Mx3000P instrument (Stratagene, La Jolla, CA). The PCR mixture contained 1 μl or 2 μl of template cDNA, SYBR Premix Ex Taq solution and 8 pmol of forward and reverse primers. Amplified products were monitored directly by measuring the increase of the dye intensity of the SYBR Green I (Molecular Probes, Eugene, OR).

### 2.4. Administration of recombinant mouse IL-4 (rIL-4) or anti-mouse IL-4 antibody


One hour after dicloxacillin administration, rIL-4 was intraperitoneally administered (0.5 or 2.0 μg of rIL-4 in 0.2 ml of sterile PBS containing 0.5% BSA) in a non-fasting condition. As a control, vehicle was administered. In the neutralization study, mice were administered anti-mouse IL-4 antibody intraperitoneally (100 μg of anti-mouse IL-4 antibody in 0.2 ml of sterile PBS), 1 h before dicloxacillin administration. As a control, rat IgG2a was administered (100 μg of rat IgG2a in 0.2 ml of sterile PBS).

### 2.5. Treatment of DK-PGD<sub>2</sub>


One hour after dicloxacillin administration, mice were administered with DK-PGD<sub>2</sub> intraperitoneally (10 μg/mouse, dissolved in 200 μl of PBS) in a non-fasting condition. As a control, vehicle was administered.

### 2.6. Measurement of plasma IL-4 level

Plasma IL-4 level was measured by enzyme-linked immunosorbent assay (ELISA) using a Ready-SET-GO! Mouse IL-4 kit according to the manufacturer's instructions.



**Fig. 1.** Plasma ALT and T-Bil levels in dicloxacillin-administered mice. Mice were administered dicloxacillin (600 mg/kg, i.p.), and plasma for ALT and T-Bil were collected 6 h after the administration. Data are mean ± SD (*n* = 4; control, 5; dicloxacillin). Significantly different from saline-administered control mice (\**p* < 0.05).



**Fig. 2.** Hepatic mRNA levels of transcription factors, cytokines and chemokines in dicloxacillin-administered mice. Mice were administered dicloxacillin (600 mg/kg, i.p.), and the hepatic IL-5, IFN- $\gamma$ , GATA-3, T-bet, ROR- $\gamma$ t, STAT6, STAT1, STAT3, Eotaxin-1, MCP-1, and MIP-2 mRNA levels were measured by real-time RT-PCR 6 h after the administration. Data are mean  $\pm$  SD ( $n=4$ ; control, 5; dicloxacillin). Significantly different from saline-administered control mice ( $p < 0.05$ ).

### 2.7. Statistical analysis

Data are presented as mean  $\pm$  SD. Statistical analyses between multiple groups were performed using one-way analysis of variance (ANOVA), followed by Tukey's post hoc test, and comparisons between two groups were carried out using two-tailed Student's *t* test in mRNA and plasma IL-4 level. In ALT and T-Bil levels, non-parametric statistical analysis was conducted using the Mann–Whitney *U* test and Kruskal–Wallis test.  $p < 0.05$  was considered statistically significant.

## 3. Results

### 3.1. Increase of plasma ALT and T-Bil levels in dicloxacillin-administered mice

Female BALB/c mice were administered dicloxacillin at a dose of 600 mg/kg. Plasma ALT and T-Bil (Fig. 1) were significantly

increased 6 h after dicloxacillin administration. The administration of dicloxacillin at a dose of 400 mg/kg did not affect on the ALT and T-Bil levels (data not shown).

### 3.2. Expression of transcription factor, cytokine, and chemokine genes in dicloxacillin-administered mouse liver

To investigate the involvement of immunological factors in the dicloxacillin hepatotoxicity, hepatic mRNA levels of IL-5, IFN- $\gamma$ , GATA-3, T-bet, ROR- $\gamma$ t, STAT6, STAT1, STAT3, Eotaxin-1, MCP-1, and MIP-2 were measured by real-time RT-PCR. IL-5, STAT6, Eotaxin-1, MCP-1, and MIP-2 expressions were significantly increased in dicloxacillin-administered mice compared with the control mice, whereas STAT1 expression was significantly decreased. Furthermore, T-bet, GATA-3, ROR- $\gamma$ t, IFN- $\gamma$ , and STAT3 expressions were

not changed (Fig. 2). These results suggested that Th2-related factors, such as IL-5, STAT6, and Eotaxin-1, were involved in the dicloxacillin-induced liver injury.

3.3. Plasma IL-4 level in dicloxacillin-administered mouse liver

IL-4 is a cytokine which activates STAT6 (Nelms et al., 1999), and is a major factor in Con A-induced hepatitis (Jaruga et al., 2003). To investigate whether IL-4 was involved in the dicloxacillin-induced liver injury, we measured plasma IL-4 in dicloxacillin-administered mice (Fig. 3). Plasma IL-4 level was significantly increased in dicloxacillin-administered group compared with the control mice.

3.4. Exacerbation of hepatotoxic effect by rIL-4 administration, and amelioration by anti-IL-4 antibody administration

To further investigate whether IL-4 was involved in the dicloxacillin-induced liver injury, we performed rIL-4 administration and IL-4 neutralization studies (Fig. 4). In the dicloxacillin/rIL-4 cotreatment study, the plasma ALT level was increased significantly and dose-dependently in mice coadministered 2.0 µg/mouse




Fig. 3. Plasma IL-4 level in dicloxacillin-administered mice. Mice were administered dicloxacillin (600 mg/kg, i.p.), and plasma was collected 6 h after the administration. Data are mean ± SD (n = 4; control, 5; dicloxacillin). Significantly different from saline-administered control mice (\*p < 0.05).




Fig. 4. Effects of recombinant mouse IL-4 (rIL-4) or anti-mouse IL-4 antibody administration on plasma ALT in dicloxacillin-administered mice. Mice were administered dicloxacillin (600 mg/kg, i.p.) and the plasma ALT was measured 6 h after the administration. In the rIL-4 administration study, rIL-4 (0.5 or 2.0 µg/mouse indicated + or ++, respectively) was administered, 1 h after dicloxacillin administration. In the IL-4 neutralization study, anti-mouse IL-4 antibody (0.1 mg/mouse, i.p.) was administered, 1 h before dicloxacillin administration. Liver specimens were prepared 6 h after the dicloxacillin administration. Liver tissue sections were stained with H&E (left photos) or immunostained with anti-MPO antibody (right photos). Data are mean ± SD (n = 4–5). Significantly different from dicloxacillin-administered group (\*p < 0.05); significantly different from dicloxacillin-plus control IgG2a administered group (†p < 0.05).

not changed (Fig. 2). These results suggested that Th2-related factors, such as IL-5, STAT6, and Eotaxin-1, were involved in the dicloxacillin-induced liver injury.

3.3. Plasma IL-4 level in dicloxacillin-administered mouse liver

IL-4 is a cytokine which activates STAT6 (Nelms et al., 1999), and is a major factor in Con A-induced hepatitis (Jaruga et al., 2003). To investigate whether IL-4 was involved in the dicloxacillin-induced liver injury, we measured plasma IL-4 in dicloxacillin-administered mice (Fig. 3). Plasma IL-4 level was significantly increased in dicloxacillin-administered group compared with the control mice.

3.4. Exacerbation of hepatotoxic effect by rIL-4 administration, and amelioration by anti-IL-4 antibody administration

To further investigate whether IL-4 was involved in the dicloxacillin-induced liver injury, we performed rIL-4 administration and IL-4 neutralization studies (Fig. 4). In the dicloxacillin/rIL-4 cotreatment study, the plasma ALT level was increased significantly and dose-dependently in mice coadministered 2.0 µg/mouse




Fig. 3. Plasma IL-4 level in dicloxacillin-administered mice. Mice were administered dicloxacillin (600 mg/kg, i.p.), and plasma was collected 6 h after the administration. Data are mean ± SD (n = 4; control, 5; dicloxacillin). Significantly different from saline-administered control mice (\*p < 0.05).





Fig. 4. Effects of recombinant mouse IL-4 (rIL-4) or anti-mouse IL-4 antibody administration on plasma ALT in dicloxacillin-administered mice. Mice were administered dicloxacillin (600 mg/kg, i.p.) and the plasma ALT was measured 6 h after the administration. In the rIL-4 administration study, rIL-4 (0.5 or 2.0 µg/mouse indicated + or ++, respectively) was administered, 1 h after dicloxacillin administration. In the IL-4 neutralization study, anti-mouse IL-4 antibody (0.1 mg/mouse, i.p.) was administered, 1 h before dicloxacillin administration. Liver specimens were prepared 6 h after the dicloxacillin administration. Liver tissue sections were stained with H&E (left photos) or immunostained with anti-MPO antibody (right photos). Data are mean ± SD (n = 4–5). Significantly different from dicloxacillin-administered group (\*p < 0.05); significantly different from dicloxacillin-plus control IgG2a administered group (†p < 0.05).





**Fig. 5.** Effects of DK-PGD<sub>2</sub> treatment on dicloxacillin-induced liver injury in mice. Mice were administered dicloxacillin (600 mg/kg, i.p.), and the plasma ALT and IL-4 levels were measured 6 h after the administration (A). One hour after dicloxacillin administration, DK-PGD<sub>2</sub> (10 μg/mouse, i.p.) was administered. Liver specimens (B) were prepared 6 h after the dicloxacillin administration. Liver tissue sections were stained with H&E (left photo) or immunostained with anti-MPO antibody (right photo). Data are mean ± SD (dicloxacillin and/or DK-PGD<sub>2</sub> administered). Significantly different from saline-administered group (\**p* < 0.05); significantly different from dicloxacillin-administered mice (†*p* < 0.05).

rIL-4 compared with only dicloxacillin-administered mice. However, rIL-4 alone did not induce liver injury in mice. In the H&E staining, infiltration of mononuclear cells into the hepatocytes was observed in the dicloxacillin/rIL-4-coadministered group but not in the dicloxacillin-administered group. In anti-MPO staining, the numbers of MPO-positive mononuclear cells were increased in the dicloxacillin/rIL-4-coadministered group compared with dicloxacillin-administered group. In the neutralization study, the i.p. administration of anti-mouse IL-4 antibody significantly reduced the plasma ALT, but rat IgG2 treatment demonstrated no effect on the dicloxacillin-induced liver injury.

### 3.5. Effects of DK-PGD<sub>2</sub> treatment

We investigated the effects of DK-PGD<sub>2</sub>, a selective CRTh2 agonist, on dicloxacillin-induced liver injury. Administration of DK-PGD<sub>2</sub> alone did not increase the plasma ALT and IL-4 levels, and DK-PGD<sub>2</sub> alone at a higher dose (50 μg/mouse, i.p.) did not increase ALT level (data not shown). The plasma ALT and IL-4 levels were significantly increased in the dicloxacillin/DK-PGD<sub>2</sub>-coadministered group compared with the saline-administered group (Fig. 5A). In the histopathological study, spotty necrosis and infiltration of MPO-positive mononuclear cells were observed in the dicloxacillin/DK-PGD<sub>2</sub>-coadministered group, but not in the dicloxacillin-administered group (Fig. 5B).

### 3.6. Effects on liver mRNA expressions in DK-PGD<sub>2</sub> administered mice

To evaluate the underlying mechanisms responsible for the increased susceptibility of DK-PGD<sub>2</sub> administered mice to

dicloxacillin-induced liver injury, the mRNA expression levels were assessed. The hepatic mRNA levels of GATA-3, Eotaxin-1, MCP-1 and MIP-2 were significantly increased compared with the dicloxacillin-administered mice (Fig. 6). Especially, MIP-2 mRNA was markedly increased. In contrast, IFN-γ, IL-5, ROR-γt, STAT3, and STAT6 were not changed, and T-bet and STAT1 were significantly decreased (data not shown).

## 4. Discussion

Adverse drug reactions to antibiotics are variable, but severe liver injury is rarely reported (Bjornsson and Olsson, 2005) and the mechanism of antibiotic-induced liver injury remains to be clarified. Dicloxacillin, penicillinase-sensitive penicillin, rarely causes liver injury and there is some evidence for an immunological idiosyncratic reaction (Olsson et al., 1992). In the present study, dicloxacillin-induced liver injury was investigated in mice. Firstly, we investigated the effects of dicloxacillin administration on ALT and T-Bil in normal female BALB/c mice (Fig. 1). BALB/c mice were previously used as a model for halothane-induced liver injury, which is mediated by immunological factors (Kobayashi et al., 2009). The ALT increase induced by dicloxacillin was attenuated after 24 h, compared with those after 6 h (data not shown). This is the first mice model to study dicloxacillin-induced liver injury. Flucloxacillin, which is structural homologue of dicloxacillin, has a higher incidence of liver injury than dicloxacillin (Bjornsson and Olsson, 2005; Olsson et al., 1992) and it has been recently reported that HLA allele is a major biomarker of DILI due to flucloxacillin (Daly et al., 2009), suggested that immune responses are mainly involved in flucloxacillin-induced liver injury. However, the mechanisms are unclear and there is no mouse model, we would like

primary biliary cirrhosis (Harada et al., 1997). In this study, IL-4 was demonstrated to be involved in the dicloxacillin-induced liver injury.

CRTh2, one of the PGD<sub>2</sub> receptors, plays a major role in atopic dermatitis, allergic asthma, and airway inflammation, and it was demonstrated that CRTh2 is responsible for PGD<sub>2</sub> chemotaxis of Th2 cells, eosinophils, basophils, and monocytes (Kostenis and Ulven, 2006). DK-PGD<sub>2</sub> is a CRTh2 selective agonist that enhances Th2-type inflammation (Spik et al., 2005). In this study, Th2-mediated immune responses were suggested to be involved in the dicloxacillin-induced liver injury, thus we hypothesized that DK-PGD<sub>2</sub> may exacerbate liver injury. The plasma ALT level was significantly increased in the dicloxacillin/DK-PGD<sub>2</sub>-coadministered group (Fig. 5). DK-PGD<sub>2</sub> enhances the chemotactic responsiveness to other chemoattractants, as well as degranulation (Kostenis and Ulven, 2006). Therefore, it was conceivable that a higher ALT level would be observed in the dicloxacillin/DK-PGD<sub>2</sub>-coadministered group than in the rIL-4/dicloxacillin-coadministered group (Figs. 4 and 5). The hepatic GATA-3 mRNA level was significantly increased in the dicloxacillin/DK-PGD<sub>2</sub>-coadministered group suggesting an increase in Th2-mediated factors in the liver, followed by an increase in the plasma IL-4 level (Nelms et al., 1999). Hepatic mRNA levels of Eotaxin-1, MCP-1, and MIP-2 levels were significantly increased in the dicloxacillin/DK-PGD<sub>2</sub>-coadministered group (Fig. 6). These chemokines induce the infiltration of neutrophils followed by necrosis. Especially, MIP-2 mRNA was markedly increased, since CRTh2 activation induces MIP-2 secretion (Takeshita et al., 2004). In this study, we demonstrated that DK-PGD<sub>2</sub> exacerbates dicloxacillin-induced liver injury due to induction of IL-4 and MIP-2, followed by the activation of Th2 cells and other immune cells.

Although the mechanisms of DILI are still unclear due to the lack of proper animal models, LPS-treated rodents become sensitive to human hepatotoxic drugs, such as sulindac, diclofenac, chlorpromazine, and trovafloxacin (Zou et al., 2009; Shaw et al., 2009). Cytokines such as TNF- $\alpha$ , IL-1, IL-6, and IFN- $\gamma$  are upregulated after the activation of Toll-like receptor 4 by LPS (Gaestel et al., 2009; Shaw et al., 2009), however the involvement of Th2 factors in drug-induced liver injury in LPS-administered rodents was never reported. Enhanced responsiveness with DK-PGD<sub>2</sub> could be a novel method in drug development to detect human hepatotoxic drugs that involve Th2-specific factors.

In conclusion, we reported that Th2 immune factors, such as IL-4, IL-5, and Eotaxin-1, were involved in drug-induced liver injury in mice, and DK-PGD<sub>2</sub> exacerbates dicloxacillin-induced liver injury via Th2 cytokines and chemokines. The present study provides new insight into the mechanisms of drug-induced liver injury.

#### Funding

Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan (H20-BIO-G001).

#### Conflict of interest

None of the authors has any conflicts of interest related to this manuscript.

#### Acknowledgement

We thank Mr. Brent Bell for reviewing the manuscript.

#### References

- Biedermann, B.T., Knelling, M., Mailhammer, R., Maier, K., Sander, C.A., Kollias, G., Kunkel, S.L., Hultner, L., Rocken, M., 2000. Mast cell control neutrophil recruitment during T cell-mediated delayed hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. *J. Exp. Med.* 192, 1441–1451.
- Bjornsson, E., Olsson, R., 2005. Outcome and prognostic markers in severe drug-induced liver disease. *Hepatology* 42, 481–489.
- Daly, A.K., Donaldson, P.T., Bhatnagar, P., et al., 2009. HLA-B\*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat. Genet.* 41, 816–819.
- Dambach, D.M., Durham, S.K., Laskin, J.D., Laskin, D.L., 2006. Distinct roles of NF- $\kappa$ B p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity. *Toxicol. Appl. Pharmacol.* 211, 157–165.
- Gaestel, M., Kotlyarov, A., Kracht, M., 2009. Targeting innate immunity protein kinase signaling in inflammation. *Nat. Rev. Drug. Discov.* 8, 480–497.
- Harada, K., Water, J.V., Leung, P.S.C., Coppel, R.L., Ansari, A., Nakanuma, Y., Gershwin, M.E., 1997. *In situ* nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. *Hepatology* 25, 791–796.
- Heneghan, M.A., McFarlane, I.G., 2002. Current and novel immunosuppressive therapy for autoimmune hepatitis. *Hepatology* 35, 7–13.
- Holt, M.P., Ju, C., 2006. Mechanisms of drug-induced liver injury. *AAPS J.* 8, 48–54.
- Jaruga, B., Hong, F., Sun, R., Radaeva, S., Gao, B., 2003. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. *J. Immunol.* 171, 3233–3244.
- Kato, A., Yoshidome, H., Edwards, M.J., Lentsch, A.B., 2000. Reduced hepatic ischemia/reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. *Inflamm. Res.* 49, 275–279.
- Kay, A.B., 2001. Allergy and allergic diseases. *N. Engl. J. Med.* 344, 30–37.
- Kidd, P., 2003. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. *Altern. Med. Rev.* 8, 223–246.
- Kita, H., Macky, I.R., Van, D.W.J., Gershwin, M.E., 2001. The lymphoid liver: considerations on pathways to autoimmune injury. *Gastroenterology* 120, 1485–1501.
- Kobayashi, E., Kobayashi, M., Tsuneyama, K., Fukami, T., Nakajima, M., Yokoi, T., 2009. Halothane-induced liver injury is mediated by interleukin-17 in mice. *Toxicol. Sci.* 111, 302–310.
- Kostenis, E., Ulven, T., 2006. Emerging roles of DP and CRTh2 in allergic inflammation. *Trends Mol. Med.* 12, 148–158.
- Kumada, T., Tsuneyama, K., Hatta, H., Ishizawa, S., Takano, Y., 2004. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. *Mod. Pathol.* 17, 1141–1149.
- Leonard, W.J., O'Shea, J.J., 1998. Jaks and STATs: biological implications. *Annu. Rev. Immunol.* 16, 293–322.
- Maddox, J.F., Domzalski, A.C., Roth, R.A., Ganey, P.E., 2004. 15-Deoxy prostaglandin J<sub>2</sub> enhances allyl alcohol-induced toxicity in rat hepatocytes. *Toxicol. Sci.* 77, 290–298.
- Nelms, K., Keegan, A.D., Zamorano, J., Ryan, J.J., Paul, W.E., 1999. The IL-4 receptor: signaling mechanisms biologic functions. *Annu. Rev. Immunol.* 17, 701–738.
- Njoku, D.B., Li, Z., Washington, N.D., Mellerson, J.L., Talor, M.V., Sharma, R., Rose, N.R., 2009. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury. *Eur. J. Immunol.* 39, 1652–1663.
- Olsson, R., Wiholm, B.E., Sand, C., Zettergren, L., Hulcrantz, R., Myehed, M., 1992. Liver damage from flucloxacillin, cloxacillin, dicloxacillin. *J. Hepatol.* 15, 154–161.
- Palmer, C.D., Restifo, P.N., 2009. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. *Trends Immunol.* 30, 592–602.
- Reilly, T.P., Brady, J.N., Marchick, M.R., Bourdi, M., George, J.W., Radonovich, M.F., Pise-Masison, C.A., Pohl, L.R., 2001. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. *Chem. Res. Toxicol.* 14, 1620–1628.
- Shaw, P.J., Ditewig, A.C., Waring, J.F., Liguori, M.J., Blomme, E.A., Ganey, P.E., Roth, R.A., 2009. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. *Toxicol. Sci.* 107, 270–280.
- Spanakis, N.E., Garinis, G.A., Alexopoulos, E.C., Patrinos, G.P., Menounos, P.G., Sklavounou, A., Manolis, N.E., Gorgoulis, V.G., Valis, D., 2002. Cytokines serum levels in patients with chronic HCV infection. *J. Clin. Lab. Anal.* 16, 40–46.
- Spik, I., Brenuchon, C., Angeli, V., Staumont, D., Fleury, S., Capron, M., Trottein, F., Dombrowicz, D., 2005. Activation of the prostaglandin D<sub>2</sub> receptor DP2/CRTH2 increases allergic inflammation in mouse. *J. Immunol.* 174, 3703–3708.
- Stein, G.E., 2005. Safety of newer parenteral antibiotics. *Clin. Infect. Dis.* 41, 293–302.
- Steinman, L., 2007. A brief history of Th17, the first major revision in the Th1/Th2 hypothesis if T cell-mediated tissue damage. *Nat. Rev. Med.* 13, 139–145.
- Takeshita, K., Yamasaki, T., Nagano, K., Sugimoto, H., Shichijo, M., Gantner, F., Bacon, B.K., 2004. CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. *Int. Immunol.* 16, 947–959.
- Zou, W., Devi, S.S., Sparkenbaugh, E., Younis, H.S., Roth, R.A., Ganey, P.E., 2009. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. *Toxicol. Sci.* 108, 184–193.

## CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay<sup>S</sup>

Atsushi Iwamura, Tatsuki Fukami, Hiroko Hosomi, Miki Nakajima, and Tsuyoshi Yokoi

*Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan*

Received November 14, 2010; accepted February 14, 2011

### ABSTRACT:

Drug-induced hepatotoxicity is a major problem in drug development, and reactive metabolites generated by cytochrome P450s are suggested to be one of the causes. CYP2C9 is one of the major enzymes in hepatic drug metabolism. In the present study, we developed a highly sensitive cell-based screening system for CYP2C9-mediated metabolic activation using an adenovirus vector expressing CYP2C9 (AdCYP2C9). Human hepatocarcinoma HepG2 cells infected with our constructed AdCYP2C9 for 2 days at multiplicity of infection 10 showed significantly higher diclofenac 4'-hydroxylase activity than human hepatocytes. AdCYP2C9-infected cells were treated with several hepatotoxic drugs, resulting in a significant increase in cytotoxicity by treatment with losartan, benzbromarone, and tienilic acid. Metabolic activation of losartan by CYP2C9 has never been reported, although the metabolic acti-

vations of benzbromarone and tienilic acid have been reported. To identify the reactive metabolites of losartan, the semicarbazide adducts of losartan were investigated by liquid chromatography-tandem mass spectrometry. Two CYP2C9-specific semicarbazide adducts of losartan (S1 and S2) were detected. S2 adduct formation suggested that a reactive metabolite was produced from the aldehyde metabolite E3179, but a possible metabolite from S1 adduct formation was not produced via E3179. In conclusion, a highly sensitive cell-based assay to evaluate CYP2C9-mediated metabolic activation was established, and we found for the first time that CYP2C9 is involved in the metabolic activation of losartan. This cell-based assay system would be useful for evaluating drug-induced cytotoxicity caused by human CYP2C9.

### Introduction

Drug-induced hepatotoxicity is a serious problem in drug development and clinical practice. In the United States, it accounts for more than 50% of cases of acute liver failure, and more than 600 drugs have been associated with hepatotoxicity (Lee, 2003; Park et al., 2005). That is why some drugs that were launched on the market were later withdrawn. Therefore, the prediction of drug-induced hepatotoxicity before clinical trials is important in drug development, and multiple cell-based assays have been developed for evaluation of drug-induced hepatotoxicity (Greer et al., 2010). Sometimes, drug-induced hepatotoxicity is associated with reactive metabolites produced by drug-metabolizing enzymes (Guengerich, 2008). However, species differences in drug-metabolizing enzymes or other factors between humans and laboratory animals are a major problem in predicting the hepatotoxicity.

This work was supported in part by Research on Advanced Medical Technology, Health and Labor Science Research from the Ministry of Health, Labor, and Welfare of Japan [Grant H20-BIO-G001].

Article, publication date, and citation information can be found at <http://dmd.aspetjournals.org>.

doi:10.1124/dmd.110.037259.

<sup>S</sup> The online version of this article (available at <http://dmd.aspetjournals.org>) contains supplemental material.

Cytochrome P450 (P450) enzymes are the most studied drug-metabolizing enzymes, accounting for ~75% of the metabolism of clinical drugs (Guengerich, 2008). Among them, CYP3A4 is the predominant isoform expressed in human liver, accounting for up to 60% of the total hepatic P450 protein and responsible for more than 50% of drug metabolism (Guengerich, 2008). To date, many researchers have tried to predict drug-induced hepatotoxicity in vitro using human hepatocarcinoma HepG2 cells, but the low expression levels of P450 enzymes in HepG2 cells may be responsible for the fact that 30% of the compounds were falsely classified as nontoxic (Rodríguez-Antona et al., 2002; Hewitt and Hewitt, 2004). Useful in vitro cell-based assays have been established with HepG2 cells, leading to improved evaluation of drug-induced cytotoxicity. For example, our previous study showed that benzodiazepines such as flunitrazepam and nimetazepam were metabolically activated by CYP3A4 by coin-cubation with HepG2 cells and CYP3A4 Supersomes (Mizuno et al., 2009). Vignati et al. (2005) demonstrated that various hepatotoxic drugs such as flutamide and troglitazone were activated by CYP3A4 using HepG2 cells transiently transfected with CYP3A4. Thus, the activation of hepatotoxic drugs by CYP3A4 has been well evaluated, but the contribution of other P450 enzymes remains to be evaluated. CYP2C is the second most highly expressed P450 subfamily in human liver, and CYP2C9 is the most highly expressed isoform in this family

**ABBREVIATIONS:** P450, cytochrome P450; Nrf2, nuclear factor-E2 p-45-related factor; GFP, green fluorescent protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; siRNA, small interfering RNA; HPLC, high-performance liquid chromatography; WST-8, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium monosodium salt; LC, liquid chromatography; MS/MS, tandem mass spectrometry; LCMS-IT-TOF, liquid chromatography ion trap time-of-flight mass spectrometry; MOI, multiplicity of infection; BSO, buthionine sulfoximine; ALT, alanine aminotransferase; FLU-1, 4-nitro-3-(trifluoromethyl)phenylamine.

(Edwards et al., 1998). CYP2C9 is responsible for the metabolism of various pharmaceutical drugs and appears to be partially involved in the generation of reactive metabolites, as is CYP3A4 (Li, 2002). For example, benzbromarone is metabolized via 6-hydroxybenzbromarone to a catechol by CYP2C9, followed by the oxidization of the catechol to a reactive *ortho*-quinone metabolite (McDonald and Rettie, 2007). Tienilic acid is metabolized to reactive intermediates, the thiophene sulfoxide or the thiophene epoxide, by CYP2C9 (Koenigs et al., 1999). In recent studies, we developed useful *in vitro* cell-based assays using adenovirus to sensitively evaluate the involvement of CYP3A4 and superoxide dismutase 2 in drug-induced cytotoxicity (Yoshikawa et al., 2009; Hosomi et al., 2010). In the present study, a highly sensitive cytotoxicity assay system for CYP2C9-mediated metabolic activation was established in a similar way, and the drug-induced cytotoxicity was evaluated with the established assay system. Drugs investigated in this study were hepatotoxic drugs that are known to be CYP2C9 substrates (flutamide, fluvastatin, losartan, terbinafine, valproic acid, and zolpidem) and those that are known to be metabolically activated by CYP2C9 (benzbromarone and tienilic acid). As a result, we found for the first time that the cytotoxicity of losartan was enhanced by CYP2C9 and then performed additional studies to identify the structures of the reactive metabolites.

#### Materials and Methods

**Chemicals and Reagents.** Diclofenac, fluvastatin, and tienilic acid were obtained from Wako Pure Chemicals (Osaka, Japan). Losartan and terbinafine were obtained from LKT Laboratories (St. Paul, MN). Benzbromarone, flutamide, valproic acid, and zolpidem were obtained from Sigma-Aldrich (St. Louis, MO). Candesartan, eprosartan, irbesartan, telmisartan, and valsartan were obtained from Toronto Research Chemicals (Ontario, ON, Canada). Olmesartan was kindly provided by Daiichi-Sankyo (Tokyo, Japan). 4'-Hydroxydiclofenac and human CYP2C9 and CYP3A4 Superomes (recombinant cDNA-expressed P450 enzymes prepared from a baculovirus insect cell system) were purchased from BD Gentest (Woburn, MA). The Adenovirus Expression Vector Kit (Dual Version) and adenovirus genome DNA-TPC were obtained from Takara Bio (Shiga, Japan). The QuickTiter Adenovirus Titer Immunoassay Kit was from Cell Biolabs (Tokyo, Japan). Stealth Select RNAi for Nrf2 (accession number NM\_006164) and Stealth RNAi Negative Control Medium GC Duplex #2 were obtained from Invitrogen (Carlsbad, CA). Dulbecco's modified Eagle's medium was from Nissui Pharmaceutical (Tokyo, Japan). Restriction enzymes were from New England Biolabs (Ipswich, MA) and Takara Bio. All primers were commercially synthesized at Hokkaido System Sciences (Sapporo, Japan). Other chemicals were of analytical or the highest grade commercially available.

**Cell Culture.** Human embryonic kidney 293 cells and human hepatocarcinoma HepG2 cells were obtained from American Type Culture Collection (Manassas, VA). The 293 and HepG2 cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (Invitrogen), 3% glutamine, 16% sodium bicarbonate, and 0.1 mM nonessential amino acids (Invitrogen) in a 5% CO<sub>2</sub> atmosphere at 37°C. Cells were infected with the adenovirus in medium containing 5% fetal bovine serum.

**Recombinant Adenovirus.** A recombinant adenovirus expressing CYP2C9 (AdCYP2C9) was constructed using the cosmid-terminal protein complex method according to the manufacturer's instructions. CYP2C9 cDNA prepared by reverse transcription-polymerase chain reaction using total RNA from human liver obtained at autopsy was inserted into the *Sma*I site of the pAxcwtit vector. The use of human liver was approved by the ethics committees of Kanazawa University (Kanazawa, Japan) and Iwate Medical University (Morioka, Japan). The nucleotide sequences of CYP2C9 were confirmed by DNA sequence analysis (Long-Read Tower DNA sequencer; GE Healthcare, Little Chalfont, Buckinghamshire, UK). This vector and the parental adenovirus DNA terminal protein complex were cotransfected into 293 cells by Lipofectamine 2000 (Invitrogen). The recombinant adenovirus was isolated and propagated into the 293 cells. In a similar way, the recombinant adenovirus vector expressing a green fluorescence protein (GFP) was generated in the previous study (Hosomi et al., 2010). Viral titers were determined by a

QuickTiter Adenovirus Titer Immunoassay Kit. The titers of AdCYP2C9 and AdGFP were  $8.6 \times 10^8$  and  $2.1 \times 10^8$  plaque-forming units/ml, respectively.

**Immunoblot Analyses of Human CYP2C9 and Nrf2.** SDS-polyacrylamide gel electrophoresis and immunoblot analyses of human CYP2C9, Nrf2, and GAPDH were performed. For human CYP2C9, total cell homogenates from adenovirus-infected HepG2 cells (5  $\mu$ g) were separated on 7.5% polyacrylamide gels and electrotransferred onto a polyvinylidene difluoride membrane, Immobilon-P (Millipore Corporation, Billerica, MA). The membrane was probed with a polyclonal rabbit anti-human CYP2C9 antibody (Daiichi Pure Chemicals, Tokyo, Japan). Biotinylated anti-rabbit IgG and a VECTASTAIN ABC Kit (Vector Laboratories, Burlingame, CA) were used for diaminobenzidine staining. For human Nrf2, total cell homogenates from siRNA-transfected and adenovirus-infected HepG2 cells (25  $\mu$ g) were separated on 7.5% polyacrylamide gels and electrotransferred onto a polyvinylidene difluoride membrane, Immobilon-P. The membrane was probed with polyclonal rabbit anti-human Nrf2 antibody (Santa Cruz Biotechnology, Inc., San Diego, CA), and the corresponding fluorescent dye-conjugated second antibody and an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE) were used for detection. For human GAPDH, SDS-polyacrylamide gel electrophoresis and immunoblot analysis were performed according to H. Hosomi, T. Fukami, A. Iwamura, M. Nakajima, and T. Yokoi (manuscript submitted for publication).

**Diclofenac 4'-Hydroxylase Activity.** HepG2 cells ( $3 \times 10^5$  cells/well) were seeded in 12-well plates. After a 24-h incubation, cells were infected with AdCYP2C9 or AdGFP for 1, 2, 3, or 5 days. Then, after a 1-h incubation with 100  $\mu$ M diclofenac, the medium was subjected to high-performance liquid chromatography (HPLC) to measure the concentration of 4'-hydroxydiclofenac, a metabolite of diclofenac catalyzed by CYP2C9. The HPLC analysis was performed using an L-2130 pump (Hitachi, Tokyo, Japan), an L-2200 autosampler (Hitachi), and a D-2500 Chromato-Integrator (Hitachi) equipped with a Mightysil RP-18 C18 GP column (5- $\mu$ m particle size, 4.6 mm i.d.  $\times$  150 mm; Kanto Chemical, Tokyo, Japan). The eluent was monitored at 280 nm. The mobile phase was 35% acetonitrile containing 20 mM sodium perchlorate (pH 2.5). The flow rate was 1.0 ml/min. The column temperature was 35°C. The retention times of 4'-hydroxydiclofenac and diclofenac were 8.1 and 22.8 min, respectively. The quantification of 4'-hydroxydiclofenac was performed by comparing the HPLC peak height with that of an authentic standard. The limit of quantification in the reaction mixture for 4'-hydroxydiclofenac was 250 nM with a coefficient of variation of <2%.

**Cytotoxicity Assay.** Nrf2 is known to regulate cytoprotective genes such as glutathione transferase, heme oxygenase-1, NAD(P)H:quinine oxidoreductase, superoxide dismutase, and UDP-glucuronosyltransferase (Copple et al., 2008). Our recent study demonstrated that drug-induced cytotoxicity could be detected with high sensitivity by the knockdown of Nrf2 in HepG2 cells (H. Hosomi, T. Fukami, A. Iwamura, M. Nakajima, and T. Yokoi, manuscript submitted for publication). Likewise, knockdown of Nrf2 was performed by siRNA transfection in this study. HepG2 cells were transfected with Stealth Select RNAi for Nrf2 (siNrf2) and Stealth RNAi Negative Control Medium GC Duplex #2 (siScramble) by Lipofectamine RNAiMAX Reagent (Invitrogen). According to the manufacturer's protocol, RNAi duplex-Lipofectamine RNAiMAX complexes were prepared and added to each well before the HepG2 cells were seeded ( $1.0 \times 10^4$  cells/well). The concentrations of siNrf2 and siScramble were 10 nM. After 24-h incubation, the cells were infected with AdCYP2C9 or AdGFP. Forty-eight hours after infection, the cells were treated with benzbromarone, tienilic acid, flutamide, fluvastatin, terbinafine, valproic acid, zolpidem, or sartans (candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan) for 24 h. After incubation with the drugs, cell viability was quantified by 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium monosodium salt (WST-8) and ATP assays according to the manufacturer's protocol. The WST-8 assay, which is a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay, was performed using a Cell Counting Kit-8 (CCK-8 kit; Wako Pure Chemicals). After incubation with the drugs for 24 h, CCK-8 reagent was added and the absorbance of WST-8 formazan was measured at 450 nm. The ATP assay was performed using a CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). After incubation with the drugs for 24 h, CellTiter-Glo Reagent was added, and the generation of a luminescent signal